SB 2047 Hawaii Senate · 2026 Regular Session

RELATING TO PHARMACY BENEFIT MANAGERS.

Summary
Establishes certain requirements for pharmacy benefit managers, other than health maintenance organizations that own and operate their own pharmacies, that reimburse contracting pharmacies for drugs on a maximum allowable cost basis. Allows contracting pharmacies to reverse and rebill claims if a maximum allowable cost is denied on appeal. Authorizes the Insurance Commissioner to assess fines for violations. Appropriates funds. Effective 7/1/3000. (HD2)
Bill status passed both 4 of 5 stages cleared
Introduction
Jan 2026
Committee Review
Mar 2026
Senate Passage
Mar 2026
House Passage
Mar 2026
Governor
Introduced Jan 14, 2026 Last action Mar 30, 2026
Maddy AI version diff · 4 comparisons

What changed between versions

SB2047_SD1 SB2047_SD2 · 6 edits
MODERATE
This bill revision updates the bill version from SD1 to SD2, correcting a section number reference from 326-106 to 328-106 regarding pharmacy benefit manager regulations. It expands the definition of 'pharmacy benefit manager' to include all managers setting maximum allowable costs, not just those with specific compliance failures, and broadens the definition of 'maximum allowable cost list' to include various pricing methodologies. The changes also clarify the complaint process and update the appropriation section to use lowercase 'insurance division' and 'department of commerce and consumer affairs'.
Scope change
The bill's scope was broadened to explicitly cover all pharmacy benefit managers that use maximum allowable cost lists, regardless of whether they previously failed to comply with repealed regulations, and the definition of the cost list now includes multiple specific pricing methods.
TECHNICAL

Corrected a reference to the repealed statute section number from 326-106 to 328-106.

Updated capitalization in the funding section to use lowercase for 'insurance division' and 'department of commerce and consumer affairs'.

DEFINITION

Changed the definition of 'contracting pharmacy' from an independent pharmacy with no competitors within ten miles to a non-affiliated pharmacy not part of a chain.

Expanded the definition of 'maximum allowable cost list' to explicitly list eight specific pricing methodologies, including average acquisition cost, average manufacturer price, and discount indexing.

REQUIREMENT

Rephrased the requirement for pharmacy benefit managers to provide reports to contracting pharmacies to make them more accessible.

Added the word 'a' before 'complaint process' to clarify that a formal process must be established.

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
25
Key actions
10
Committee
13
Mar 30, 2026
Lower · Passed
Report adopted; referred to the committee(s) on FIN as amended in HD 2 with none voting aye with reservations; none voting no (0) and Representative(s) Cochran, Lowen, Perruso, Quinlan excused (4).
lower
Mar 30, 2026
Committee
Reported from CPC (Stand. Com. Rep. No. 1483-26) as amended in HD 2, recommending referral to FIN.
lower
Mar 24, 2026
Lower · Passed
The committee on CPC recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 11 Ayes: Representative(s) Matayoshi, Grandinetti, Chun, Ilagan, Ichiyama, Iwamoto, Kong, Lowen, Marten, Tam, Pierick; Ayes with reservations: none; Noes: none; and Excused: none.
lower
Mar 20, 2026
Committee
Reported from HLT (Stand. Com. Rep. No. 1278-26) as amended in HD 1, recommending passage on Second Reading and referral to CPC.
lower
Mar 18, 2026
Lower · Passed
The committee on HLT recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 8 Ayes: Representative(s) Takayama, Keohokapu-Lee Loy, Amato, Marten, Olds, Takenouchi, Alcos, Garcia; Ayes with reservations: none; Noes: none; and 1 Excused: Representative(s) Hartsfield.
lower
Mar 12, 2026
Committee
Referred to HLT, CPC, FIN, referral sheet 17
lower
Mar 10, 2026
Introduced
Received from Senate (Sen. Com. No. 156) in amended form (SD 2).
lower
Mar 10, 2026
Upper · Passed
Report adopted; Passed Third Reading, as amended (SD 2). Ayes, 25; Aye(s) with reservations: none . Noes, 0 (none). Excused, 0 (none). Transmitted to House.
upper
Mar 3, 2026
Upper · Passed
The committee(s) on WAM recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in WAM were as follows: 12 Aye(s): Senator(s) Dela Cruz, Moriwaki, DeCoite, Elefante, Hashimoto, Inouye, Kanuha, Kidani, Kim, Lee, C., Richards, Wakai; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Fevella.
upper
Mar 3, 2026
Upper · Passed
The committee(s) on CPN recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in CPN were as follows: 4 Aye(s): Senator(s) Keohokalole, Fukunaga, Lamosao, McKelvey; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Awa.
upper
Feb 27, 2026
Upper · Passed
The committee(s) on CPN/WAM will hold a public decision making on 03-03-26 10:16AM; Conference Room 211 & Videoconference.
upper
Feb 11, 2026
Upper · Passed
Report adopted; Passed Second Reading, as amended (SD 1) and referred to CPN/WAM.
upper
Feb 11, 2026
Committee
Reported from HHS (Stand. Com. Rep. No. 2200) with recommendation of passage on Second Reading, as amended (SD 1) and referral to CPN/WAM.
upper
Feb 3, 2026
Committee
Re-Referred to HHS, CPN/WAM.
upper
Feb 2, 2026
Upper · Passed
The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, McKelvey, Kanuha, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.
upper
Jan 30, 2026
Upper · Passed
The committee(s) on HHS has scheduled a public hearing on 02-02-26 1:05PM; Conference Room 225 & Videoconference.
upper
Jan 22, 2026
Committee
Referred to HHS, CPN.
upper
Jan 21, 2026
Introduced
Introduced and passed First Reading.
upper
Jan 14, 2026
Introduced
Pending Introduction.
upper
6 primary · 0 co-sponsors

Sponsors